Prohibits health insurers, health care plans and HMOs from requiring prior authorization for anti-retroviral medication used to treat and prevent HIV infection.
Summary
Bill S05012 aims to amend the public health law and insurance law in New York by prohibiting health insurers, health care plans, and HMOs from requiring prior authorization for anti-retroviral medications used to treat and prevent HIV infection. This legislation is designed to improve access to necessary medications for individuals living with or at risk of HIV, thereby facilitating timely treatment and prevention efforts. The bill specifies that while prior authorization cannot be required, insurers still retain the right to deny claims if the services are deemed not medically necessary after the fact.
Impact
If enacted, this bill would significantly alter the landscape of prescription drug coverage for anti-retroviral medications in New York. It would eliminate a common barrier to accessing these critical medications, potentially leading to improved health outcomes for individuals affected by HIV. The changes would affect various stakeholders, including health insurers, healthcare providers, and patients, by streamlining the process for obtaining necessary medications without the delays often associated with prior authorization requirements.
Sentiment
The sentiment surrounding Bill S05012 appears to be largely supportive, as it addresses a crucial public health issue and aims to enhance access to essential medications for HIV treatment and prevention. However, there may be concerns from some insurers regarding the potential implications for cost management and medical necessity determinations, which could lead to a nuanced debate during the legislative process.
Contention
Notable points of contention may arise from insurance companies and healthcare plans, which could express concerns about the financial impact of removing prior authorization requirements. They may argue that such measures are necessary to control costs and ensure that medications prescribed are medically necessary. Advocates for public health and HIV prevention, on the other hand, would likely argue that the benefits of increased access to anti-retroviral medications outweigh these concerns, emphasizing the importance of timely treatment in managing public health outcomes.
Prohibits Medicaid service providers from requiring prior authorization for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
Prohibits health insurance plans from requiring prior authorization for a new episode of rehabilitative care for twelve visits, or from requiring prior authorization for rehabilitative care for chronic pain for ninety days.
Prohibits Medicaid service providers from requiring prior authorization for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
State rapid start program established; operation of local rapid start programs to treat patients who are HIV-positive provided; prior authorization, cost sharing, and step therapy for antiretroviral therapy and HIV prevention services prohibited; and money appropriated.